ATRenew Inc.
NYSE:RERESpecialty Retail
-$0.07 today
- Market cap
- $1.34B
- Beta
- 0.24
- P/E (TTM)
- 22.3
- EPS (TTM)
- $1.18
- Dividend yield
- 2.56%
Volume 0.52M
Average 1.05M
RERE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ATRenew Inc.NYSE: RERE
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of CN¥73.4M rose 33.7% year over year, ahead of the +22.0% change in trailing-twelve-month research & development. Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.
Context
- Research & development amounted to 1.2% of revenue in FY2025, down 0.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.7% holds above the trailing-twelve-month pace of +22.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CNY · from the income statement
- Latest · FY2025
- 237.27M CNY
- Year-over-year change
- +12.8%
- 4-year CAGR
- -2.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 237.27M | +12.8% |
| FY2024 | 2024-12-31 | 210.36M | +7.5% |
| FY2023 | 2023-12-31 | 195.68M | -14.1% |
| FY2022 | 2022-12-31 | 227.81M | -13.9% |
| FY2021 | 2021-12-31 | 264.56M | — |
Research & Development vs competitors
How RERE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.0% is the highest of 2, against a peer median of -100.0%.
- Research & development amounts to 1.2% of revenue for RERE, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥262.31M CNY | +22.0% | +1.4% | 1.2% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding RERE) | — | -100.0% | — | 0.0% | |
Competitors are the stored peer set for RERE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78B | 9.87B | 12.97B | 16.33B | 20.47B |
| Cost of Revenue | 5.74B | 7.6B | 10.34B | 13.09B | 17.96B |
| Gross Profit | 2.04B | 2.27B | 2.63B | 3.24B | 2.52B |
| Gross Margin | 26.3% | 23.0% | 20.3% | 19.9% | 12.3% |
| Research & Development | 264.56M | 227.81M | 195.68M | 210.36M | 237.27M |
| Selling, General & Admin | 1.64B | 1.77B | 1.52B | 1.67B | 1.93B |
| Operating Expenses | 2.94B | 4.9B | 2.8B | 3.21B | 2.11B |
| Depreciation & Amortization | 373.75M | 405.41M | 333.73M | 333.73M | 113.13M |
| EBITDA | (521.33M) | (2.16B) | 192.38M | 362.7M | 515.78M |
| EBITDA Margin | -6.7% | -21.9% | 1.5% | 2.2% | 2.5% |
| Operating Income | (895.07M) | (2.62B) | (173.34M) | 28.97M | 402.66M |
| Operating Margin | -11.5% | -26.6% | -1.3% | 0.2% | 2.0% |
| Interest Income | 8.37M | 17.78M | 37.88M | 26.86M | 19.94M |
| Interest Expense | 16.78M | 6.16M | 7.06M | 15.02M | 5.87M |
| Other Income / Expenses | (65.34M) | 43.94M | (25.44M) | (94.08M) | (20.33M) |
| Income Before Tax | (960.41M) | (2.58B) | (198.78M) | (65.11M) | 382.33M |
| Pre-Tax Margin | -12.3% | -26.1% | -1.5% | -0.4% | 1.9% |
| Income Tax Expense | (143.86M) | (111.78M) | (42.53M) | (56.88M) | 55.2M |
| Net Income | (816.55M) | (2.47B) | (156.25M) | (8.23M) | 327.13M |
| Net Margin | -10.5% | -25.0% | -1.2% | -0.1% | 1.6% |
| EPS (Basic) | (9.17) | (10.11) | (0.64) | (0.03) | 0.89 |
| EPS (Diluted) | (9.17) | (10.11) | (0.64) | (0.03) | 0.89 |
| Weighted Avg Shares | 89.01M | 244.19M | 243.24M | 242.43M | 362.96M |
| Weighted Avg Shares (Diluted) | 144.46M | 244.23M | 243.24M | 242.43M | 364.94M |
ATRenew Inc.
NYSE:RERE
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.